MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Meeting: 2019 International Congress

Abstract Number: 94

Keywords: COMT inhibitors, Pharmacotherapy

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations.

Background: OPC, a once-daily COMT inhibitor, proved effective in the treatment of motor fluctuations in PD patients in two large, pivotal, multinational trials (BIPARK-I and II) [1],[2].

Method: Patient-level data from matching treatment arms in BIPARK-I and II were combined in placebo (PLC) and OPC-50mg groups. The studies had similar designs (primary efficacy endpoint: change from baseline in patient diaries-based absolute OFF-time) and eligibility criteria [1],[2]. An exploratory post-hoc analysis was performed to evaluate the influence of disease severity (assessed by modified Hoehn and Yahr, H&Y <2.5 vs >=2.5) on efficacy outcomes (i.e., change from baseline in OFF-/ON-time). Applied linear regression’s slope was statistically tested for deviation from zero and linearity.

Results: In total, 1027 patients were randomized to BIPARK-I and II and 522 patients took a dose of study medication; Full Analysis Set comprised 517 [PLC (n=255); OPC-50mg (n=262)]. Two PLC patients with H&Y=4 were excluded from disease severity analysis as there were no OPC-50mg matched-patients. For OPC-50mg, OFF-/ON-time magnitude of responses was not influenced (non-significant linear regression). For PLC, the higher H&Y staging at baseline the greater magnitude of OFF-/ON-time response at endpoint (ending in a linear regression slope statistically significant).

Conclusion: Disease severity impacted OFF-/ON-time magnitude of responses for PLC but not OPC-50mg patients in a clinical study setting.

References: [1] Ferreira et al., Lancet Neurology 2016; 15(2):154-165. [2] Lees et al., JAMA Neurol. 2017; 74(2):197-206.

To cite this abstract in AMA style:

H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva. Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/influence-of-disease-severity-in-the-efficacy-response-of-parkinsons-disease-patients-with-motor-fluctuations-post-hoc-analysis-from-combined-bipark-i-and-ii/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/influence-of-disease-severity-in-the-efficacy-response-of-parkinsons-disease-patients-with-motor-fluctuations-post-hoc-analysis-from-combined-bipark-i-and-ii/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley